Figures & data
Figure 3 Atorvastatin attenuated interleukin-1β expression in the hippocampus of a rat treated with Aβ1-42. The upper panel shows interleukin-1β-positive cells in rat hippocampus, detected by immunohistochemistry on day 7 after Aβ injection (original magnification × 400). (A) Control group (group 1), (B) atorvastatin control group (group 2), (C) AD group (group 3), and (D) atorvastatin-treated AD group (group 4). (E) The lower panel shows the number of interleukin-1β-positive cells counted in the rat hippocampus.
Notes: The data are presented as the mean ± standard deviation. *P < 0.01.
Abbreviations: Aβ, amyloid-beta peptide; IL, interleukin; AD, Alzheimer’s disease.
Figure 4 Atorvastatin attenuated interleukin-6 expression in the hippocampus of a rat treated with Aβ 1-42. The upper panel shows interleukin-6-positive cells in rat hippocampus, detected by immunohistochemistry on day 7 after Aβ injection (original magnification × 400). (A) Control group (group 1), (B) atorvastatin control group (group 2), (C) AD group (group 3), and (D) atorvastatin-treated AD group (group 4). (E) The lower panel shows the number of interleukin-6-positive cells counted in the rat hippocampus.
Notes: The data are presented as the mean ± standard deviation. *P < 0.01.
Abbreviations: Aβ, amyloid-beta (peptide); IL, interleukin; AD, Alzheimer’s disease.
Figure 5 Atorvastatin attenuated TNF-α expression in hippocampus of the Aβ1-42-treated rat. The upper panel shows TNF-α-positive cells in rat hippocampus, detected by immunohistochemistry on day 7 after Aβ injection (original magnification × 400). (A) Control group (group 1), (B) atorvastatin control group (group 2), (C) AD group (group 3), and (D) atorvastatin-treated AD group (group 4). (E) The lower panel shows the number of TNF-α-positive cells counted in the rat hippocampus.
Abbreviations: Aβ, amyloid-beta (peptide); IL, interleukin; AD, Alzheimer’s disease; TNF-α, tumor necrosis factor alpha.
